Probiotic treatment for infants with atopic dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of the probiotic Bifidobacterium longum CCFM1029 on infants aged 1 to 3 years diagnosed with atopic dermatitis. The study is designed as a double-blind trial, where participants are randomly assigned to receive either the probiotic or a placebo for a duration of nine months. The primary outcome measures include changes in the eczema area and severity index (EASI) scores, as well as various blood markers related to allergies and inflammation. Evaluations will occur every three months to assess the efficacy of the probiotic in reducing symptoms and inflammatory responses associated with atopic dermatitis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects were between 1 and 3 years old.
* For patients diagnosed with atopic dermatitis by a professional physician and the EASI score is greater than 10, the type and frequency of drugs used during the experiment should be recorded.
* The subject's parents agree to join the trial and sign the informed consent form.

Exclusion Criteria:

* The patient who has a history of allergic reactions, or the use of other highly sensitive or contraindicated drugs (allergy to antibiotics or antipyretics).
* The patient who has taken oral immunosuppressants and systemic steroids within the past 2 weeks.
* The patient who has consumed probiotic-related products (including drops, lozenges, capsules, powder or yogurt) within the past 1 month.
* The patient who has participated in other clinical studies within the past 1 month.
* The patient who has received immunotherapy within the past 1 year.
* The patient who suffering from major diseases (with a IC card for severe illness), congenital diseases.
* The patient who is not suitable to participate in the trial as assessed by the professional physician.

Where it's running

• Glac Biotech Co., Ltd.
  Tainan City, Taiwan Recruiting

Study contacts

• Study coordinator: Hung-Chih Lin, M.D., Ph.D
• Email: d0373@mail.cmuh.org.tw
• Phone: 886-4-22052121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• ADBest TREAT Registry for adults with atopic dermatitis

  A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07904546

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

• Tilrekimig for moderate-to-severe eczema in teens and adults

  A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.

  Recruiting at 31 sites Phase 3 Pfizer · Birmingham, Alabama and 49 other locations · NCT07783425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.